Clinical Trial Update: A Study of IBI363 in Subjects with Advanced Solid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study of IBI363 in advanced solid malignancies is currently recruiting, with indications including melanoma, non-small cell lung cancer, colorectal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• IBI363

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Melanoma, Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING